Effect of leukopenia induced by cyclophosphamide on the initial stage of arterial thrombosis in mice

Thromb Res. 2021 Oct:206:111-119. doi: 10.1016/j.thromres.2021.08.017. Epub 2021 Aug 24.

Abstract

Introduction: Leukocytes are found in organizing thrombi and are associated with thrombus growth. However, their role in the initial stage of thrombus formation is not well known. We investigated the role of leukocytes in the early stage of arterial thrombosis by inducing leukopenia.

Methods: In this double-blind, randomized, placebo-controlled study, 72 Institute of Cancer Research mice were randomly treated with intraperitoneal 100 mg/kg cyclophosphamide or normal saline. The primary outcome was time to occlusion after FeCl3 treatment. We also compared thrombus size, histological composition, and association with peripheral blood cell counts between cyclophosphamide and control groups.

Results: Cyclophosphamide treatment significantly decreased leukocyte counts by 82.8% compared to placebo (P < 0.001). The time to occlusion was significantly longer in the cyclophosphamide group (3.31 ± 1.59 min) than in the control group (2.30 ± 1.14 min; P = 0.003). The immunoreactivity for Ly6G-positive cells, intracellular histone H3, and released histone H3 in thrombi was significantly reduced in the cyclophosphamide group by 92.8%, 50.2%, and 34.3%, respectively. Time to occlusion had a moderate negative correlation with leukocyte count in peripheral blood (r = -0.326, P = 0.022) in the entire group.

Conclusions: Cyclophosphamide-induced leukopenia attenuated thrombus formation during the early stage of arterial thrombosis. Our findings suggest the potential role of leukocytes in the initial stage of arterial thrombosis.

Keywords: Cyclophosphamide; Leukopenia; Neutrophil; Neutrophil extracellular trap; Thrombosis.

MeSH terms

  • Animals
  • Cyclophosphamide / adverse effects
  • Leukocyte Count
  • Leukocytes
  • Leukopenia* / chemically induced
  • Leukopenia* / drug therapy
  • Mice
  • Thrombosis* / chemically induced
  • Thrombosis* / drug therapy

Substances

  • Cyclophosphamide